3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
2
Prostatic Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
10
Nivolumab
5
Gemcitabine
4
durvalumab
3
Specimen Handling
3
Sirolimus
3
Magnetic Resonance Spectroscopy
3
Docetaxel
3
Cryosurgery
3
Cisplatin
3
Blood Specimen Collection
3
tremelimumab
2
temsirolimus
2
pertuzumab
2
pegilodecakin
2
enzalutamide
2
cabozantinib
2
alvocidib
2
Vorinostat
2
Trastuzumab
2
Ritonavir
2
Radiotherapy
2
Radiosurgery
2
Psychiatric Rehabilitation
2
Paclitaxel
2
Oxaliplatin
2
Interleukin-2
2
Cyclophosphamide
2
Carboplatin
2
Biopsy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Sevoflurane
×
Dermatologic
×
Clear all
NCT04074460
2022-06-09
VAPOR-C
Peter MacCallum Cancer Centre, Australia
Phase 4
Completed
169 enrolled